Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline

Eli Lilly has dropped a PD-L1/TIM-3 bispecific antibody from its clinical pipeline. The asset moved into a phase 1 advanced solid tumor trial late last year but was culled from the pipeline before delivering final data.